If you'd invested in: Renishaw and GlaxoSmithKline
Measuring-equipment maker Renishaw has seen profits leap, but investors are sceptical about the prospects for drugmaker GSK.
GSK: on the mend?
Glaxo’s chief executive has stepped down after nine years at the top. Has he left the pharma giant in good health? Alex Rankine reports.
A golden hello that says big companies aren't hearing us
When it comes to ridiculous executive pay, GlaxoSmithKline still doesn't get it, says Merryn Somerset Webb. But they're not the only ones.
A fantastic investment weapon for private investors
Ed Bowsher explains the 'secret weapon' that could help private investors generate excellent market-beating returns.
If this corporate giant breaks up, shareholders should prosper
The boss of pharmaceutical giant GSK has hinted the company could be split in two. That would be great news for shareholders, says Ed Bowsher.
Don’t be tempted to buy banks – here are two better options
Bank shares might look cheap right now, but don't be tempted. There are better places to put your money, says Ed Bowsher. Here, he picks two stocks to…